GLP1R and diabetes mellitus: Our results demonstrate that GLP-1 receptor agonists provide better cardiovascular protection than SGLT2 inhibitors in patients with HFpEF and DM, significantly reducing the risk of cardiovascular events, progression to SHF, and stroke.